383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping
Year: 2020
Type: article
Source: Annals of Oncology
Authors: J.C-H. Yang, X. Le, B.C. Cho, J-Y. Han, M. Morise, Y-M. Chen, J-H. Kang, T. Kato, H. Takeoka, K. Chikamori, H. Sakai, K. Park, Y-L. Wu, K. Schumacher, R. Bruns, J. Straub, P. Paik
Institutions: National Taiwan University Hospital, The University of Texas MD Anderson Cancer Center, Yonsei University, Yonsei Cancer Hospital, National Cancer Center, National Cancer Center Hospital, Nagoya University, Taipei Veterans General Hospital, National Yang Ming University, The Catholic University of Korea Seoul St. Mary's Hospital, Kanagawa Cancer Center, National Kyushu Medical Center, National Sanyo Hospital, Saitama Cancer Center, Samsung Medical Center, Sungkyunkwan University, Guangdong Academy of Medical Sciences, Guangdong Provincial People's Hospital, Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, F. Hoffmann-La Roche, Merck KGaA, Taiho Pharmaceutical, Exelixis, Celldex Therapeutics, Les Laboratories Pierre Fabre, Five Prime Therapeutics, Mersana Therapeutics, BeiGene, Boehringer Ingelheim Japan, Incyte, Yuhan, MacroGenics, Eisai, Kyowa Hakko Kirin, Astellas Pharma, Shionogi, Ono Pharmaceutical, Ipsen, Genentech, EMD Serono, Pfizer Japan, Chugai Pharmaceutical, MSD K.K., Eli Lilly Japan, Ignyta, Daiichi Sankyo Europe
OpenAlex ID: W3108905923